Disc Medicine develops investigational treatments for serious hematologic diseases by targeting red blood cell biology, including heme biosynthesis and iron homeostasis. News about IRON centers on its clinical-stage pipeline, including bitopertin for erythropoietic protoporphyria, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders.
Recurring updates include clinical trial progress, medical-meeting presentations, FDA communications, quarterly financial results, business updates, investor-conference participation, and leadership or organizational changes tied to the company’s development and commercialization planning.
Disc Medicine (NASDAQ:IRON) completed enrollment in its Phase 3 APOLLO trial of bitopertin in EPP (expanded to 183 patients) and expects topline APOLLO data in Q4 2026. The company will present updated Phase 2 DISC-0974 data at ASCO and anticipates multiple Q4 2026 readouts. Cash, cash equivalents, and marketable securities were $730.2 million as of March 31, 2026, funding operations into 2029.
Disc Medicine (NASDAQ:IRON) will present Phase 2 RALLY-MF data for investigational DISC-0974 in anemia of myelofibrosis at ASCO 2026 in Chicago, with oral presentation on June 2, 2026.
The abstract (No. 6501) posts online on May 21, 2026; additional, previously unpresented data will be disclosed at the conference. DISC-0974 remains investigational and is not approved for use.
Disc Medicine (NASDAQ:IRON) announced completion of enrollment in the pivotal Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP).
The study was expanded from 150 to 183 participants due to demand, enrolled in less than one year, includes sites in the US, Canada, Europe, and Australia, and plans to report results in Q4 2026 with an FDA decision expected by mid-2027.
Disc Medicine (NASDAQ:IRON) reported Q4 and full-year 2025 results and a program update on Feb 26, 2026. Key points: $791.2M cash runway into 2029, Phase 3 APOLLO for bitopertin enrolling through March 2026 with topline data expected Q4 2026, FDA issued a CRL in Feb 2026. Positive Phase 2 data presented for DISC-0974 in MF anemia; DISC-3405 studies progressing with data due 2H 2026.
Full-year 2025: R&D $170.6M, SG&A $65.4M, net loss $212.2M; cash increased from $489.9M at 2024 year-end largely from $454.4M equity offerings.
Disc Medicine (NASDAQ:IRON) announced management will present at multiple investor conferences in early March 2026, including TD Cowen (Mar 3), Leerink Global Healthcare (Mar 9), Jefferies Biotech on the Beach (Mar 10) and Barclays Healthcare (Mar 11).
Live webcasts of the presentations will be accessible via the company's investor relations website and archived replays will be available after each event.
Disc Medicine (NASDAQ:IRON) received a Complete Response Letter from the FDA for bitopertin in erythropoietic protoporphyria (EPP). The FDA agreed trials show bitopertin lowers whole blood metal-free PPIX but found no demonstrated link to sunlight-exposure clinical endpoints.
The FDA said results from the ongoing Phase 3 APOLLO study could support traditional approval; topline data are anticipated in Q4 2026. Disc completed APOLLO enrollment in March 2026, plans a Type A meeting, expects an updated FDA decision by mid-2027, and reported approximately $791 million cash at Dec 31, 2025, with runway into 2029.
Disc Medicine (NASDAQ:IRON) appointed Lisa Amaya Price, MBA as Chief Human Resources Officer effective January 12, 2026.
Ms. Amaya Price has 25+ years of HR and organizational leadership experience at commercial-stage and large life-science companies. Disc granted an inducement award consisting of: an option for 37,500 shares (exercise price = closing price on grant date), an RSU for 25,000 shares, and a supplemental RSU for 4,000 shares.
Vesting: the option vests 25% on January 12, 2027, then monthly over 36 months; the RSU vests 25% annually starting February 15, 2026; the supplemental RSU vests quarterly in eight 12.5% installments starting February 15, 2026.
Disc Medicine (NASDAQ:IRON) outlined 2025 achievements and 2026 priorities focused on hematology programs. Key 2025 highlights include an NDA submission for bitopertin accepted under the accelerated approval pathway with a Commissioner’s National Priority Voucher (CNPV), positive initial Phase 2 data for DISC-0974 in anemia of myelofibrosis, initiation of DISC-3405 studies in polycythemia vera and sickle cell disease, a Composition of Matter patent for DISC-0974 through 2041, and $791 million cash and equivalents as of Dec 31, 2025 providing runway into 2029.
Planned 2026 milestones include an FDA decision on bitopertin under CNPV, US launch preparation if approved, multiple Phase 2 updates for DISC-0974 and DISC-3405 in H2 2026, an End of Phase 2 meeting for DISC-0974, and initiation of a Phase 2 trial in IBD-related anemia.
Disc Medicine (NASDAQ:IRON) announced that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 pm PT / 6:00 pm ET. A live webcast will be available via the company's investor relations website at ir.discmedicine.com, and an archived replay will be posted after the event.
Disc Medicine (NASDAQ:IRON) presented positive initial RALLY-MF Phase 2 data for DISC-0974 in myelofibrosis (MF) with anemia at ASH on December 6, 2025. The open-label study had enrolled 47 patients with 34 included in the responder analysis as of the October 16 cutoff.
Key findings: >75% hepcidin reductions, increases in serum iron, hematologic responses across subgroups (63% nTD ≥1 g/dL ≥12 weeks; 71% TD Low transfusion independence over 16 weeks; 67% TD High ≥50% transfusion reduction). DISC-0974 was generally well tolerated. Additional data expected H2 2026.